LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Partnership with Lilly Expands Qiagen’s Personalized Healthcare Pipeline

By LabMedica International staff writers
Posted on 03 Jun 2014
Print article
Qiagen (Hilden, Germany) and Eli Lilly (Indianapolis, Indiana, USA) will codevelop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen’s multimodal, multianalyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test. The development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with cancer therapies under development by Lilly.

Qiagen offers companion diagnostic programs spanning a range of molecular testing platforms, including real-time polymerase chain reaction (PCR) assays for use on Qiagen’s QIAsymphony family and next-generation sequencing (NGS) panels. QIAGEN also offers a novel, multimodal, multianalyte platform from PrimeraDx. The proprietary technology enables laboratories to process multiple samples in a fast, cost-efficient run. The technology allows the analysis of dozens of DNA and RNA biomarkers as well as their copy numbers, expression levels and mutations in one assay and at the same time.

The Modaplex platform was cleared by the US Food and Drug Administration (FDA; Silver Spring, MD, USA) in December 2013.

“We believe our technology can enhance Lilly’s development of innovative therapies for the benefit of cancer patients. In addition to a broad portfolio of PCR-based assays targeting more than 25 biomarkers, Qiagen’s Personalized Healthcare offering has expanded to include universal solutions using next-generation sequencing (NGS) and now also a unique and proprietary multimodal, multianalyte testing technology. Our collaborations with Lilly are among more than 20 co-development and co-commercialization projects underway with leading pharmaceutical and biotechnology companies.”

Richard B. Gaynor, MD, Senior VP, Oncology-Clinical Product Development and Medical Affairs, of Lilly, said: “Certain applications in biomarker development for tailoring oncology therapeutics require the combined analysis of DNA and RNA, and this collaboration provides a multimodal, multianalyte solution that can process multiple sample types and biomarkers in a single test.”

Related Links:

Qiagen
Eli Lilly
FDA


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more